NCT02710149

A Clinical Research of CD20-Targeted CAR-T in B Cell Malignancies

• Status: Unknown
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 45 (estimated)
• Sponsor: Southwest Hospital, China · Academic / Other
• Sex: All
• Age: 14 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The main purpose of this study is to explore the therapeutic effect of CD20-targeted chimeric antigen receptor T(CAR-T) cells in the treatment of B cell malignancies.

Detailed description

The anti-CD20 antibody has been broadly used in the treatment of B cell malignancies and exhibited good clinical outcomes. The CD19-targeted CAR-T has shown exellent therapeutic efficiency in B cell malignancies,especially in acute lymphocytic leukemia. However, patients treated with CD19-targeted CAR-T may face relapse of CD19 mutation. Other targets aimed CAR-T is in need. Therefore we constructed CD20-targeted CAR-T cells and hope to start a clinicaltrial to explore the therapeutic effect of CD20-targeted CAR-T cells in the treatment of B cell malignancies.

Conditions

• Leukemia
• Lymphoma

Interventions

Type	Name	Description
BIOLOGICAL	Anti-CD20-CAR-transduced T cells	Patients receive autologous-derived CD20-targeted CAR-T cells on day 1, 2 after receiving lymphodepleting chemotherapy.

Timeline

• Start date: 2016-03-01
• Primary completion: 2020-03-01
• Completion: 2021-03-01
• First posted: 2016-03-16
• Last updated: 2019-06-25

Locations

1 site across 1 country: China